Skip to content
      Award Recognizes Entrepreneurial Excellence in Technology Category

CHICAGO, June 30 /PRNewswire-FirstCall/ — Allscripts, the leading
provider of clinical software and information solutions that physicians use to
improve healthcare, today announced that Glen Tullman, Chief Executive
Officer, received the Ernst & Young Entrepreneur Of The Year(R) 2008 Award in
the Technology Category in the Midwest regional program. The award recognizes
outstanding entrepreneurs who are building and leading dynamic, growing
businesses. Mr. Tullman was selected by an independent panel of judges, and
the award was presented at a gala event at the Hilton Chicago on June 26,


“I’m thankful to our employees for their incredible efforts in delivering
each and every day for our clients and truly appreciate Ernst & Young
recognizing the success that we have achieved at Allscripts,” said Mr.
Tullman. “At Allscripts, we believe we can make a real difference in the
world by transforming healthcare. This award is testimony to our ability to
deliver on that vision, with strong solutions that tens of thousands of
physicians and other healthcare professionals use every day to enhance
quality, improve safety, and more effectively manage costs.”

The prestigious Ernst & Young Entrepreneur Of The Year awards celebrate
their 22nd anniversary this year. The program honors entrepreneurs who have
demonstrated exceptionality in such areas as innovation, financial performance
and personal commitment to their businesses and communities.

“Ernst & Young is pleased to honor outstanding business leaders such as
Glen Tullman,” said Randy Tavierne, Ernst & Young Strategic Growth Partner.
“Winners of the Entrepreneur Of The Year award build leading businesses and
contribute a great deal to the communities around them. Their success helps
our area grow stronger.”

Under Mr. Tullman’s leadership, Allscripts has grown from a small provider
of repackaged medications to an industry leader with a client base of more
than 40,000 physicians in 5,000 clinics, 800 hospitals and 6,000 extended care
facilities nationwide. The latest evidence of Mr. Tullman’s vision and
leadership skills is the announced merger of Allscripts with Misys Healthcare.
When finalized, the merger will double the company’s size and build a
powerhouse for healthcare transformation with a client base of approximately
one-third the practicing physicians in the U.S.

Mr. Tullman is a member of the Board of Trustees of the Certification
Commission on Healthcare Information Technology. He also serves on the
International Board of Directors of the Juvenile Diabetes Research Foundation,
fulfilling his view that “We should measure today’s corporate leaders not by
what they get, but rather by what they give.”

As a Midwest award winner, Mr. Tullman is now eligible for consideration
for the Ernst & Young Entrepreneur Of The Year 2008 national program. Award
winners in several national categories, as well as the overall national Ernst
& Young Entrepreneur Of The Year award winner, will be announced at the annual
awards gala in Palm Springs, California on November 15, 2008. The awards are
the culminating event of the Ernst & Young Strategic Growth Forum, the
nation’s most prestigious gathering of high-growth, market-leading companies.

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and
advisory services. Worldwide, our 130,000 people are united by our shared
values and an unwavering commitment to quality. We make a difference by
helping our people, our clients and our wider communities achieve potential.
For more information, please visit

Ernst & Young refers to the global organization of member firms of Ernst &
Young Global Limited, each of which is a separate legal entity. Ernst & Young
Global Limited, a UK company limited by guarantee, does not provide services
to clients.

About Allscripts

Allscripts (Nasdaq: MDRX) is the leading provider of clinical software,
connectivity and information solutions that physicians use to improve
healthcare. The company’s unique solutions inform, connect and transform
healthcare, delivering improved care at lower cost. More than 40,000
physicians and thousands of other healthcare professionals in clinics,
hospitals and extended care facilities nationwide utilize Allscripts to
automate everyday tasks such as writing prescriptions, documenting patient
care, managing billing and scheduling, and safely discharging patients, as
well as to connect with key information and stakeholders in the healthcare
system. To learn more, visit Allscripts at

Important Additional Information and Where to Find It

This communication is being made in respect of the proposed business
combination involving Allscripts Healthcare Solutions, Inc. (“Allscripts”) and
Misys Healthcare Systems, LLC (“MHS”), a wholly owned subsidiary of Misys plc
(“Misys”). In connection with this proposed transaction, Allscripts intends to
file with the Securities and Exchange Commission (the “SEC”) a preliminary
proxy statement, a definitive proxy statement and other related materials. The
definitive proxy statement will be mailed to the stockholders of Allscripts.
security holders can obtain copies of Allscripts’ materials (and all other
offer documents filed with the SEC) when available, at no charge on the SEC’s
website: Copies can also be obtained at no charge by directing a
request for such materials to Allscripts at 222 Merchandise Mart Plaza, Suite
2024, Chicago, Illinois 60654, Attention: Lee Shapiro, Secretary. Investors
and security holders may also read and copy any reports, statements and other
information filed by Allscripts with the SEC, at the SEC public reference room
at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-
SEC-0330 or visit the SEC’s website for further information on its public
reference room. Allscripts’ directors, executive officers and other members of
management and employees may, under the rules of the SEC, be deemed to be
participants in the solicitation of proxies from the stockholders of
Allscripts in favor of the proposed transaction. Information about Allscripts,
its directors and its executive officers, and their ownership of Allscripts’
securities, is set forth in its Form 10-K/A, which was filed with the SEC on
April 25, 2008. Additional information regarding the interests of those
persons may be obtained by reading the proxy statement and other relevant
materials to be filed with the SEC when they become available.

Forward-looking Statements

This communication contains forward-looking statements. Those
forward-looking statements include all statements other than those made solely
with respect to historical fact. Forward-looking statements may be identified
by words such as “believes”, “expects”, “anticipates”, “estimates”,
“projects”, “intends”, “should”, “seeks”, “future”, “continue”, or the
negative of such terms, or other comparable terminology. Such statements
include, but are not limited to, statements about the expected benefits of the
transaction involving Allscripts, MHS and Misys, including potential synergies
and cost savings, future financial and operating results, and the combined
company’s plans and objectives. In addition, statements made in this
communication about anticipated financial results, future operational
improvements and results or regulatory approvals are also forward-looking
statements. Such forward-looking statements are subject to numerous risks,
uncertainties, assumptions and other factors that are difficult to predict and
that could cause actual results to vary materially from those expressed in or
indicated by them. Factors that could cause actual results to differ
materially include, but are not limited to: (1) the occurrence of any event,
development, change or other circumstances that could give rise to the
termination of the merger agreement; (2) the outcome of any legal proceedings
that have been or may be instituted against Allscripts, Misys or MHS and
others following announcement of entering into the merger agreement; (3) the
inability to complete the proposed transaction due to the failure to obtain
stockholder or shareholder approval or the failure of any party to satisfy
other conditions to completion of the proposed transaction, including the
expiration of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, and the receipt of other required
regulatory approvals; (4) risks that the proposed transaction disrupts current
plans and operations and potential difficulties in employee retention as a
result of the merger; (5) the ability to recognize the benefits of the merger;
(6) legislative, regulatory and economic developments; and (7) other factors
described in filings with the SEC. Many of the factors that will determine the
outcome of the subject matter of this communication are beyond Allscripts’,
Misys’ and MHS’ ability to control or predict. Allscripts can give no
assurance that any of the transactions related to the merger will be completed
or that the conditions to the merger will be satisfied. Allscripts undertakes
no obligation to revise or update any forward-looking statement, or to make
any other forward-looking statements, whether as a result of new information,
future events or otherwise. Allscripts is not responsible for updating the
information contained in this communication beyond the published date, or for
changes made to this communication by wire services or Internet service

SOURCE  Allscripts
    -0-                             06/30/2008
    /CONTACT:  Dan Michelson, Chief Marketing Officer, +1-312-506-1217,, or Todd Stein, Senior Manager-Public Relations,
+1-312-506-1216,, both of Allscripts/
             AP Archive:
             PRN Photo Desk,
    /Web site: /

CO:  Allscripts; Ernst & Young
ST:  Illinois

-- AQM107 --
6439 06/30/2008 12:14 EDT
Scroll To Top